Evidence map›Paper›PMID 38066523›Full record

ReviewExperimental hematology & oncology2023

The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment.

Mengyuan Li, Ping Jiang, Yuhan Yang, Liting Xiong, Shuhua Wei, Junjie Wang, Chunxiao Li

Open access · goldAbstract readReview
In one paragraph

Review in Experimental hematology & oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mengyuan LiDepartment of Radiation Oncology, Peking University Third Hospital, Beijing, 100191, China.
Ping JiangDepartment of Radiation Oncology, Peking University Third Hospital, Beijing, 100191, China.
Yuhan YangDepartment of Radiation Oncology, Peking University Third Hospital, Beijing, 100191, China.
Liting XiongDepartment of Radiation Oncology, Peking University Third Hospital, Beijing, 100191, China.
Shuhua WeiDepartment of Radiation Oncology, Peking University Third Hospital, Beijing, 100191, China.
Junjie WangDepartment of Radiation Oncology, Peking University Third Hospital, Beijing, 100191, China. junjiewang_edu@sina.cn.
Chunxiao LiDepartment of Radiation Oncology, Peking University Third Hospital, Beijing, 100191, China. chunxiaoli@pku.edu.cn.
Peking University Third Hospital · CNPeking University · CN

Funding

National Natural Science Foundation of China 82073335National Natural Science Foundation of China 82173174
6 · The paper itself

Abstract

Pyroptosis, an inflammatory programmed cell death, distinguishes itself from apoptosis and necroptosis and has drawn increasing attention. Recent studies have revealed a correlation between the expression levels of many pyroptosis-related genes and both tumorigenesis and progression. Despite advancements in cancer treatments such as surgery, radiotherapy, chemotherapy, and immunotherapy, the persistent hallmark of cancer enables malignant cells to elude cell death and develop resistance to therapy. Recent findings indicate that pyroptosis can overcome apoptosis resistance amplify treatment-induced tumor cell death. Moreover, pyroptosis triggers antitumor immunity by releasing pro-inflammatory cytokines, augmenting macrophage phagocytosis, and activating cytotoxic T cells and natural killer cells. Additionally, it transforms "cold" tumors into "hot" tumors, thereby enhancing the antitumor effects of various treatments. Consequently, pyroptosis is intricately linked to tumor development and holds promise as an effective strategy for boosting therapeutic efficacy. As the principal executive protein of pyroptosis, the gasdermin family plays a pivotal role in influencing pyroptosis-associated outcomes in tumors and can serve as a regulatory target. This review provides a comprehensive summary of the relationship between pyroptosis and gasdermin family members, discusses their roles in tumor progression and the tumor immune microenvironment, and analyses the underlying therapeutic strategies for tumor treatment based on pyroptotic cell death.

Indexed as

Cell deathGasdermin familyImmunotherapyPyroptosisTumor microenvironmentTumor progression

Identifiers

PMID38066523
PMCPMC10704735
OpenAlexW4389480727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.